Global Neulasta (Pegfilgrastim) and Biosimilar Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neulasta (Pegfilgrastim) and Biosimilar Market Insights, Forecast to 2034
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
Global Neulasta (Pegfilgrastim) and Biosimilar market is expected to reach to US$ 2586 million in 2023, with a positive growth of %, compared with US$ 2431 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Neulasta (Pegfilgrastim) and Biosimilar industry is evaluated to reach US$ 3773.3 million in 2034. The CAGR will be 6.5% during 2023 to 2034.
Globally, Neulasta (Pegfilgrastim) and Biosimilar key manufacturers include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc. Amgen, Viatris, Coherus are top 3 players and held % sales share in total in 2024.
When considering the consumption regions, % volume of Neulasta (Pegfilgrastim) and Biosimilar were sold to North America, Europe and Asia Pacific in 2024. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole Neulasta (Pegfilgrastim) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.
Neulasta (Pegfilgrastim) and Biosimilar can be divided into Brand and Biosimilar, etc. Brand is the mainstream product in the market, accounting for % sales share globally in 2024 and the proportion will be % in 2034.
Neulasta (Pegfilgrastim) and Biosimilar is widely used in various fields, such as Hospital, Pharmacy and Other,, etc. Hospital provides greatest supports to the Neulasta (Pegfilgrastim) and Biosimilar industry development. In 2024, global % sales of Neulasta (Pegfilgrastim) and Biosimilar went into Hospital filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Neulasta (Pegfilgrastim) and Biosimilar market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Neulasta (Pegfilgrastim) and Biosimilar market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Segment by Type
Brand
Biosimilar
Hospital
Pharmacy
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Neulasta (Pegfilgrastim) and Biosimilar plant distribution, commercial date of Neulasta (Pegfilgrastim) and Biosimilar, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Neulasta (Pegfilgrastim) and Biosimilar introduction, etc. Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Neulasta (Pegfilgrastim) and Biosimilar
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Neulasta (Pegfilgrastim) and Biosimilar market is expected to reach to US$ 2586 million in 2023, with a positive growth of %, compared with US$ 2431 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Neulasta (Pegfilgrastim) and Biosimilar industry is evaluated to reach US$ 3773.3 million in 2034. The CAGR will be 6.5% during 2023 to 2034.
Globally, Neulasta (Pegfilgrastim) and Biosimilar key manufacturers include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc. Amgen, Viatris, Coherus are top 3 players and held % sales share in total in 2024.
When considering the consumption regions, % volume of Neulasta (Pegfilgrastim) and Biosimilar were sold to North America, Europe and Asia Pacific in 2024. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole Neulasta (Pegfilgrastim) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.
Neulasta (Pegfilgrastim) and Biosimilar can be divided into Brand and Biosimilar, etc. Brand is the mainstream product in the market, accounting for % sales share globally in 2024 and the proportion will be % in 2034.
Neulasta (Pegfilgrastim) and Biosimilar is widely used in various fields, such as Hospital, Pharmacy and Other,, etc. Hospital provides greatest supports to the Neulasta (Pegfilgrastim) and Biosimilar industry development. In 2024, global % sales of Neulasta (Pegfilgrastim) and Biosimilar went into Hospital filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global Neulasta (Pegfilgrastim) and Biosimilar market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Neulasta (Pegfilgrastim) and Biosimilar market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Segment by Type
Brand
Biosimilar
Segment by Application
Hospital
Pharmacy
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Neulasta (Pegfilgrastim) and Biosimilar plant distribution, commercial date of Neulasta (Pegfilgrastim) and Biosimilar, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Neulasta (Pegfilgrastim) and Biosimilar introduction, etc. Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Neulasta (Pegfilgrastim) and Biosimilar
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices